Stryker Co. (NYSE:SYK) has received an average recommendation of “Hold” from the twenty ratings firms that are currently covering the company. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $135.38.

A number of analysts have weighed in on SYK shares. Needham & Company LLC restated a “sell” rating on shares of Stryker in a research note on Wednesday, January 25th. Oppenheimer Holdings Inc. set a $135.00 price target on Stryker and gave the company a “hold” rating in a research note on Saturday, April 8th. Wells Fargo & Co restated an “outperform” rating and issued a $134.50 price target on shares of Stryker in a research note on Saturday, January 28th. Jefferies Group LLC raised their price target on Stryker from $120.00 to $132.00 and gave the company a “hold” rating in a research note on Wednesday, January 25th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $140.00 price target (up from $135.00) on shares of Stryker in a research note on Wednesday, April 26th.

In related news, insider Timothy J. Scannell sold 13,322 shares of the firm’s stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $135.89, for a total transaction of $1,810,326.58. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 7.80% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in SYK. Independent Advisor Alliance bought a new position in Stryker during the fourth quarter worth about $107,000. FUKOKU MUTUAL LIFE INSURANCE Co bought a new position in Stryker during the fourth quarter worth about $108,000. Bollard Group LLC raised its position in Stryker by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock worth $109,000 after buying an additional 3 shares in the last quarter. Salem Investment Counselors Inc. bought a new position in Stryker during the third quarter worth about $116,000. Finally, Baystate Wealth Management LLC raised its position in Stryker by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock worth $139,000 after buying an additional 22 shares in the last quarter. 75.29% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Stryker (NYSE:SYK) traded up 0.91% on Tuesday, reaching $139.90. The company had a trading volume of 1,446,576 shares. The firm’s 50 day moving average is $133.77 and its 200 day moving average is $125.09. Stryker has a 12 month low of $106.48 and a 12 month high of $140.30. The firm has a market capitalization of $52.29 billion, a PE ratio of 31.44 and a beta of 0.80.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, April 25th. The medical technology company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.05. The business had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $2.90 billion. Stryker had a return on equity of 23.86% and a net margin of 14.54%. The company’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same period last year, the firm earned $1.24 earnings per share. On average, equities research analysts expect that Stryker will post $6.43 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, July 31st. Investors of record on Friday, June 30th will be issued a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date is Wednesday, June 28th. Stryker’s dividend payout ratio is currently 39.08%.

TRADEMARK VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/05/23/stryker-co-syk-given-average-recommendation-of-hold-by-brokerages.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

12 Month Chart for NYSE:SYK

Receive News & Ratings for Stryker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Co. and related companies with MarketBeat.com's FREE daily email newsletter.